Renalytix Plc
RENXF
$0.02
-$0.01-35.66%
OTC PK
| 12/31/2025 | 09/30/2025 | 12/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.46% | -40.23% | -36.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.46% | -40.23% | -36.65% |
| Cost of Revenue | -- | -- | -13.60% | -16.51% | -18.89% |
| Gross Profit | -- | -- | 209.21% | -103.45% | -85.10% |
| SG&A Expenses | -- | -- | -36.31% | -33.82% | -31.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -47.19% | -27.56% | -23.27% |
| Operating Income | -- | -- | 50.20% | 26.52% | 22.23% |
| Income Before Tax | -- | -- | 44.03% | 5.44% | 0.90% |
| Income Tax Expenses | -- | -- | -100.00% | -65.22% | -70.83% |
| Earnings from Continuing Operations | -- | -- | 44.04% | 5.47% | 0.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 44.04% | 5.47% | 0.94% |
| EBIT | -- | -- | 50.20% | 26.52% | 22.23% |
| EBITDA | -- | -- | 50.37% | 26.55% | 22.42% |
| EPS Basic | -- | -- | 57.45% | 23.10% | 20.54% |
| Normalized Basic EPS | -- | -- | 61.11% | 31.20% | 23.61% |
| EPS Diluted | -- | -- | 57.83% | 28.40% | 25.61% |
| Normalized Diluted EPS | -- | -- | 61.11% | 31.20% | 23.61% |
| Average Basic Shares Outstanding | -- | -- | 49.43% | 23.74% | 25.19% |
| Average Diluted Shares Outstanding | -- | -- | 49.43% | 23.74% | 25.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |